Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.
You may also be interested in...
GlaxoSmithKline Augments Antibacterial Franchise With Pliva Purchase
$50 mil. acquisition of the Croatian lab that gave Pfizer Zithromax could provide GSK with a successor to Augmentin.
GlaxoSmithKline Augments Antibacterial Franchise With Pliva Purchase
$50 mil. acquisition of the Croatian lab that gave Pfizer Zithromax could provide GSK with a successor to Augmentin.
Sanctura Co-Promotion Deal
Esprit Pharma has become Indevus' new co-promotion partner for Sanctura (trospium), after acquiring marketing rights for the overactive bladder agent from Pliva